New combo pill slashes stubborn cholesterol in High-Risk patients
Disease control
Completed
This phase 3 study tested a daily pill that combines two drugs, obicetrapib and ezetimibe, in 407 adults with inherited high cholesterol or heart disease. Participants were already on maximum cholesterol-lowering therapy. The goal was to see if the combo pill could further lower …
Phase: PHASE3 • Sponsor: NewAmsterdam Pharma • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC